ENDPOINTS

#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV drug

Here are some of the most compelling HIV updates from the annual Conference on Retroviruses and Opportunistic Infections in San Francisco: Merck details Phase 3 wins for two-drug regimen Merck said Wednesday that a two ...

Mar 12, 2025 - 16:29
 0
#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV drug
Here are some of the most compelling HIV updates from the annual Conference on Retroviruses and Opportunistic Infections in San Francisco: Merck details Phase 3 wins for two-drug regimen Merck said Wednesday that a two ...
Read More

Tags:

Previous Article

Sun Rises on Crew-10 at Launch Pad

Next Article

Natural gas is making a comeback. Here’s what to do about it

Related Posts

IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third Harmonic

IN8bio’s Phase 1 AML data; Layoffs at Q32 Bio and Third...

Feb 11, 2025  0

Chinese ADC biotech lets Hong Kong IPO filing lapse

Chinese ADC biotech lets Hong Kong IPO filing lapse

Feb 25, 2025  0

Hims’ Super Bowl ad has drawn ire from lawmakers — and now Novo Nordisk

Hims’ Super Bowl ad has drawn ire from lawmakers — and ...

Feb 10, 2025  0